Middle East & Africa Sarcopenia Treatment Market Forecast to 2030 - Regional Analysis - by Treatment Type and Distribution Channel

Description

List of Tables

The Middle East & Africa sarcopenia treatment market was valued at US$ 66.59 million in 2022 and is expected to reach US$ 90.55 million by 2030; it is estimated to register a CAGR of 3.9% from 2022 to 2030.

Rising Awareness About Sarcopenia Bolster Middle East & Africa Sarcopenia Treatment Market

The growing awareness of sarcopenia and its negative impact on health presents a significant scope for advancements in the fields of healthcare and geriatric care. Many advocacy groups and organizations are proactively taking steps to raise the awareness of sarcopenia among the masses. These organizations often work with medical professionals to keep the public updated on the various aspects of certain disorders, such as pathogenicity, target patients, prevention, and treatments, along with underlining the value of prompt diagnosis and treatment. In line with OWH's "Stronger than Sarcopenia" campaign, women are urged to discuss sarcopenia with their healthcare providers, followed by undergoing screen for the illness and taking appropriate therapy if required.

Sarcopenia has been included in the curricula of medical schools and training programs for healthcare professionals such as physicians, nurses, and physical therapists. For example, the OWH worked with Medscape Education to create continuing medical education (CME) credits for healthcare professionals, which will better equip them to detect and treat sarcopenia in their patients. Mainstream media has expanded its coverage of sarcopenia to include articles, news stories, and documentaries. Thus, the elevating awareness regarding sarcopenia is likely to bring new growth trends into the sarcopenia treatment market in the coming years.

Middle East & Africa Sarcopenia Treatment Market Overview

The Middle East & Africa sarcopenic treatment market is segmented into Saudi Arabia, the UAE, South Africa, and the Rest of MEA. The UAE and Saudi Arabia are among the most significant contributors to the market due to the rising incidence of orthopedic disorders. Increasing awareness among the large population about the use and benefits of nutritional supplements also benefits the market progress.

An increased risk of sarcopenia in South Africa is associated with the aging population, and inadequate food security and nutrient intake brought on by poverty. The sarcopenia treatment market in this country is anticipated to be driven by a distinct population-specific approach taken by health authorities for the diagnosis, treatment, and prevention of sarcopenia.

Middle East & Africa Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)

Middle East & Africa Sarcopenia Treatment Market Segmentation

The Middle East & Africa sarcopenia treatment market is categorized into treatment type, distribution channel, and country.

Based on treatment type, the Middle East & Africa sarcopenia treatment market is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held the largest Middle East & Africa sarcopenia treatment market share in 2022.

In terms of distribution channel, the Middle East & Africa sarcopenia treatment market is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held the largest Middle East & Africa sarcopenia treatment market share in 2022.

By country, the Middle East & Africa sarcopenia treatment market is segmented into Saudia Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. South Africa dominated the Middle East & Africa sarcopenia treatment market share in 2022.

Abbott Laboratories, Bayer AG, Nestle Health Science SA, Novartis AG, Pfizer Inc, Sanofi SA, Amway Corp, and GSK Plc are some of the leading companies operating in the Middle East & Africa sarcopenia treatment market.

Product Code: BMIRE00030473

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Middle East & Africa Sarcopenia Treatment Market - Key Industry Dynamics

4.1 Middle East & Africa Sarcopenia Treatment Market - Key Industry Dynamics
4.2 Market Drivers
- 4.2.1 Upsurge in Geriatric Population
- 4.2.2 Rise in Malnutrition and Vitamin Deficiency Among Adults
4.3 Key Market Restraints:
- 4.3.1 Unavailability of Direct Interventions
4.4 Key Market Opportunities:
- 4.4.1 Products in Clinical Trial Phases
4.5 Future Trends:
- 4.5.1 Rising Awareness About Sarcopenia
4.6 Impact of Drivers and Restraints:

5. Sarcopenia Treatment Market - Middle East & Africa Market Analysis

5.1 Middle East & Africa Sarcopenia Treatment Market Revenue (US$ Million), 2020 - 2030
5.2 Middle East & Africa Sarcopenia Treatment Market Forecast and Analysis

6. Middle East & Africa Sarcopenia Treatment Market Analysis - By Treatment Type

6.1 Vitamin D and Calcium Supplement
- 6.1.1 Overview
- 6.1.2 Vitamin D and Calcium Supplement: Middle East & Africa Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
6.2 Protein Supplement
- 6.2.1 Overview
- 6.2.2 Protein Supplement : Middle East & Africa Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
6.3 Vitamin B12 Supplement
- 6.3.1 Overview
- 6.3.2 Vitamin B12 Supplement: Middle East & Africa Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
6.4 Others
- 6.4.1 Overview
- 6.4.2 Others : Middle East & Africa Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)

7. Middle East & Africa Sarcopenia Treatment Market Analysis - By Distribution Channel

7.1 Pharmacies
- 7.1.1 Overview
- 7.1.2 Pharmacies : Middle East & Africa Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)
7.2 Retail Channels
- 7.2.1 Overview
- 7.2.2 Retail Channels : Middle East & Africa Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
7.3 Online Channels
- 7.3.1 Overview
- 7.3.2 Online Channels : Middle East & Africa Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
7.4 Others
- 7.4.1 Overview
- 7.4.2 Others : Middle East & Africa Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)

8. Middle East & Africa Sarcopenia Treatment Market - Country Analysis

8.1 Middle East & Africa
- 8.1.1 Middle East & Africa Sarcopenia Treatment Market Revenue and Forecast and Analysis - By Country
  - 8.1.1.1 Middle East & Africa Sarcopenia Treatment Market Revenue and Forecast and Analysis - By Country
  - 8.1.1.2 South Africa Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 8.1.1.2.1 South Africa Sarcopenia Treatment Market Breakdown by Treatment Type
    - 8.1.1.2.2 South Africa Sarcopenia Treatment Market Breakdown by Distribution Channel
  - 8.1.1.3 Saudi Arabia Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 8.1.1.3.1 Saudi Arabia Sarcopenia Treatment Market Breakdown by Treatment Type
    - 8.1.1.3.2 Saudi Arabia Sarcopenia Treatment Market Breakdown by Distribution Channel
  - 8.1.1.4 United Arab Emirates Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 8.1.1.4.1 United Arab Emirates Sarcopenia Treatment Market Breakdown by Treatment Type
    - 8.1.1.4.2 United Arab Emirates Sarcopenia Treatment Market Breakdown by Distribution Channel
  - 8.1.1.5 Rest of Middle East & Africa Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 8.1.1.5.1 Rest of Middle East & Africa Sarcopenia Treatment Market Breakdown by Treatment Type
    - 8.1.1.5.2 Rest of Middle East & Africa Sarcopenia Treatment Market Breakdown by Distribution Channel

9. Sarcopenia Treatment Market-Industry Landscape

9.1 Overview
9.2 Growth Strategies in the Sarcopenia Treatment Market
9.3 Inorganic Growth Strategies
- 9.3.1 Overview
9.4 Organic Growth Strategies
- 9.4.1 Overview

10. Company Profiles

10.1 Abbott Laboratories
- 10.1.1 Key Facts
- 10.1.2 Business Description
- 10.1.3 Products and Services
- 10.1.4 Financial Overview
- 10.1.5 SWOT Analysis
- 10.1.6 Key Developments
10.2 Bayer AG
- 10.2.1 Key Facts
- 10.2.2 Business Description
- 10.2.3 Products and Services
- 10.2.4 Financial Overview
- 10.2.5 SWOT Analysis
- 10.2.6 Key Developments
10.3 Nestle Health Science SA
- 10.3.1 Key Facts
- 10.3.2 Business Description
- 10.3.3 Products and Services
- 10.3.4 Financial Overview
- 10.3.5 SWOT Analysis
- 10.3.6 Key Developments
10.4 Novartis AG
- 10.4.1 Key Facts
- 10.4.2 Business Description
- 10.4.3 Products and Services
- 10.4.4 Financial Overview
- 10.4.5 SWOT Analysis
- 10.4.6 Key Developments
10.5 Pfizer Inc
- 10.5.1 Key Facts
- 10.5.2 Business Description
- 10.5.3 Products and Services
- 10.5.4 Financial Overview
- 10.5.5 SWOT Analysis
- 10.5.6 Key Developments
10.6 Sanofi SA
- 10.6.1 Key Facts
- 10.6.2 Business Description
- 10.6.3 Products and Services
- 10.6.4 Financial Overview
- 10.6.5 SWOT Analysis
- 10.6.6 Key Developments
10.7 Amway Corp
- 10.7.1 Key Facts
- 10.7.2 Business Description
- 10.7.3 Products and Services
- 10.7.4 Financial Overview
- 10.7.5 SWOT Analysis
- 10.7.6 Key Developments
10.8 GSK Plc
- 10.8.1 Key Facts
- 10.8.2 Business Description
- 10.8.3 Products and Services
- 10.8.4 Financial Overview
- 10.8.5 SWOT Analysis
- 10.8.6 Key Developments

11. Appendix

11.1 About The Insight Partners
11.2 Glossary of Terms